Literature DB >> 23742880

Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy.

Zichao Luo1, Ping Li, Jizhe Deng, Ningning Gao, Yijuan Zhang, Hong Pan, Lanlan Liu, Ce Wang, Lintao Cai, Yifan Ma.   

Abstract

Modern subunit vaccines with purified or recombinant antigens are important alternatives to the traditional vaccines. However, there remains a big challenge to elicit potent antibody production and CD8 T cell response. Nanoparticle-based antigen delivery systems have emerged as an innovative strategy to improve the efficacy of subunit vaccines. The present study reported self-assembled cationic micelles based on poly(ethylene glycol)-b-poly(L-lysine)-b-poly(L-leucine) (PEG-PLL-PLLeu) hybrid polypeptides as a simple and potent vaccine delivery system. The results showed that the PEG-PLL-PLLeu micelles spontaneously encapsulated OVA antigens with great loading capacity (LC=55%) and stability. More importantly, the polypeptide micelle formulations robustly enhanced vaccine-induced antibody production by 70-90 fold, which could be due to their capability of inducing dendritic cell maturation, enhancing antigen uptake and presentation, as well as promoting germinal center formation. Furthermore, the polypeptide micelles could simultaneously encapsulate OVA and polyriboinosinic: polyribocytidylic acid (PIC), a TLR3 agonist, to synergistically augment tumor specific cytotoxic-T-lymphocyte (CTL) response. Hence, the polypeptide micelle-based antigen delivery system could be a robust adjuvant to enhance vaccine-induced immune responses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody production; Cytotoxic T-lymphocyte response; Dendritic cells; Polypeptide micelles; Vaccine adjuvant

Mesh:

Substances:

Year:  2013        PMID: 23742880     DOI: 10.1016/j.jconrel.2013.05.027

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  17 in total

Review 1.  Applications of nanomaterials as vaccine adjuvants.

Authors:  Motao Zhu; Rongfu Wang; Guangjun Nie
Journal:  Hum Vaccin Immunother       Date:  2014-11-17       Impact factor: 3.452

2.  Aluminum (Oxy)Hydroxide Nanosticks Synthesized in Bicontinuous Reverse Microemulsion Have Potent Vaccine Adjuvant Activity.

Authors:  Xu Li; Stephanie Hufnagel; Haiyue Xu; Solange A Valdes; Sachin G Thakkar; Zhengrong Cui; Hugo Celio
Journal:  ACS Appl Mater Interfaces       Date:  2017-06-29       Impact factor: 9.229

3.  Self-Assembly as a Molecular Strategy to Improve Immunotherapy.

Authors:  Eugene Froimchuk; Sean T Carey; Camilla Edwards; Christopher M Jewell
Journal:  Acc Chem Res       Date:  2020-10-19       Impact factor: 22.384

4.  Silencing c-Rel in macrophages dampens Th1 and Th17 immune responses and alleviates experimental autoimmune encephalomyelitis in mice.

Authors:  Hongling Zhang; Jiacheng Bi; Huqiang Yi; Tingting Fan; Qingguo Ruan; Lintao Cai; Youhai H Chen; Xiaochun Wan
Journal:  Immunol Cell Biol       Date:  2017-02-16       Impact factor: 5.126

Review 5.  Nanomaterials for cancer immunotherapy.

Authors:  Wantong Song; Sara N Musetti; Leaf Huang
Journal:  Biomaterials       Date:  2017-09-17       Impact factor: 12.479

Review 6.  Polymeric micro- and nanoparticles for immune modulation.

Authors:  Elana Ben-Akiva; Savannah Est Witte; Randall A Meyer; Kelly R Rhodes; Jordan J Green
Journal:  Biomater Sci       Date:  2018-12-18       Impact factor: 6.843

Review 7.  Micelle-Based Adjuvants for Subunit Vaccine Delivery.

Authors:  Thomas Trimaille; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2015-09-25

Review 8.  Recent Advances and Future Perspectives in Polymer-Based Nanovaccines.

Authors:  Natassa Pippa; Maria Gazouli; Stergios Pispas
Journal:  Vaccines (Basel)       Date:  2021-05-26

Review 9.  Recent advances of biomaterials in biotherapy.

Authors:  Ling Li; Zhi-Yao He; Xia-Wei Wei; Yu-Quan Wei
Journal:  Regen Biomater       Date:  2016-03-05

10.  The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.

Authors:  Signe Tandrup Schmidt; Swapnil Khadke; Karen Smith Korsholm; Yvonne Perrie; Thomas Rades; Peter Andersen; Camilla Foged; Dennis Christensen
Journal:  J Control Release       Date:  2016-08-26       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.